Coenzyme

NAD+

NAD+ is a coenzyme present in all cells. The app lists a half-life of about 45 minutes; in a 2019 infusion study of 8 men, plasma NAD+ did not rise until after 2 hours.1

Moderate evidenceGet the app

Level after one dose

NAD+ after one dose: 50% at ~45 min, 25% at 90 min, 12.5% at 135 min.

Drawn from the half-life in the app's model, ~45 min. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

7%The 9th most tracked compound in Milligram: of people who track compounds in Milligram logged NAD+ in the last 90 days.

Schedule

  1. Daily32%
  2. Every other day36%
  3. Twice a week27%
  4. Weekly3%
  5. Less often2%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 25 and 75 mg per dose; the median was 50 mg.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging NAD+ who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

NAD+ (nicotinamide adenine dinucleotide), also written NAD or NAD plus, is a coenzyme present in all cells of the body.1 Covarrubias and colleagues, in Nature Reviews Molecular Cell Biology in 2021, describe it as a coenzyme for redox reactions that is central to energy metabolism, and as an essential cofactor for non-redox enzymes including sirtuins, CD38 and poly(ADP-ribose) polymerases.2

A 2026 systematic review by Gallagher and Emmanuel covered 113 eligible intervention studies from January 2010 to October 2025, 33 in people (28 randomised, 5 nonrandomised) and 80 in rodents, and reported that "No eligible outcomes trials evaluated intravenous or intramuscular NAD⁺ itself for anti-aging or wellness indications."4 The six studies of NAD+ itself cited here have 11 to 180 people each.1,10,9,11,12,3

A search of PubMed on 16 November 2026 for NAD+ or nicotinamide adenine dinucleotide in the title, with "subcutaneous" in the title or summary and the human filter, returned 11 records, and none of the 11 titles reports NAD+ injected under the skin in people.

The figures at the top of the page, a half-life of about 45 minutes, 95% bioavailability, a typical dose of 50 to 250 mg a day and a time to peak of about 30 minutes, are the Milligram app’s own. None of the studies cited here reports any of them for NAD+. The "Moderate Evidence" badge at the top is the app’s own grade for NAD+, not a rating of the studies cited here.

In cells

Covarrubias and colleagues write that NAD+ is "continually turned over" by three classes of consuming enzymes: the NAD+ glycohydrolases (CD38, CD157 and SARM1), "the protein deacylase family of sirtuins and PARPs", and that these generate nicotinamide as a by-product.2

Outside cells

In the discussion of their 2019 infusion study, Grant and colleagues state that NAD+ "is unable to cross cellular membranes passively and therefore must be actively transported across the membrane".1

Levels by age

Three papers measured NAD+ in people of different ages, and none gave NAD+ to anyone. Massudi and colleagues, PLoS One, 2012, took skin samples from 49 patients aged 15 to 77 and newborn babies and reported a negative correlation between tissue NAD+ and age in men (r = −0.706, p = 0.001) and in women (r = −0.537, p = 0.01).5 Zhu and colleagues, Proceedings of the National Academy of Sciences, 2015, used a magnetic resonance method in the brains of healthy volunteers and reported "age-dependent reductions in NAD(+), total NAD contents, and NAD(+)/NADH redox potential of the healthy human brain".6 Clement and colleagues, Rejuvenation Research, 2019, measured plasma from healthy people aged 20 to 87, and reported that those aged 60 and over had significantly lower NAD+ and NADP+ than those aged 20 to 40, while NAM, MeNAM, ADPR and NADPH were significantly higher in those aged 60 and over.7

Clement and colleagues give their own limit: "our sample size of 30 subjects, split by sex, is relatively small for detailed correlations".7 In mice, Camacho-Pereira and colleagues reported that "CD38 is required for the age-related NAD decline and mitochondrial dysfunction".8

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~45 min
Bioavailability
95%
Typical dose
50–250 mg/day
Route
SubQ
Time to peak
~30 min

The app lists a half-life of about 45 minutes and a time to peak of about 30 minutes for NAD+ given subcutaneously. No cited study measured either figure.

Table 4.1Half-life and pharmacokinetics4 rows
MeasureApp figureReported in studies
Half-life~45 minNo cited study measured a plasma half-life. The 2019 infusion study saw no plasma change until after 2 hours of a continuous infusion.1 The introduction of a 2026 oral trial paper states "rapid systemic clearance (half-life ~1.7 h)" for intravenous NAD+, with no reference given for that figure.3
Time to peak~30 minIn the infusion study, plasma NAD+ first rose after the 2 hour sample, was 398% above baseline at 6 hours (the end of the infusion) and was still above baseline at 8 hours.1
Bioavailability95%None of the studies cited here, and none of the 11 titles from the PubMed query on 16 November 2026, reports a subcutaneous figure. The 2026 oral trial paper states that oral NAD+ bioavailability estimates are below 2%.3
RouteSubQIntravenous, intramuscular and oral in the studies cited here.

The chart below draws the app’s one-compartment model with its half-life of 45 minutes and time to peak of 30 minutes, with a daily interval because most of the cited trials gave NAD+ once a day.9,10,11,12 It is an illustration only. Measured plasma NAD+ in the infusion study did not follow a curve like this: it did not change until after 2 hours of a continuous infusion.1

Level over 3 days

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: every day9. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).

An illustration from a pharmacokinetic model using a half-life of 0.75 hours. It is not a measured level or a suggested dose.

Deeper analysis: Grant and colleagues, 2019

Grant and colleagues (Sydney Adventist Hospital and collaborators, Frontiers in Aging Neuroscience, 2019) randomised 11 healthy men aged 30 to 55 to a test group (n = 8) or a saline control group (n = 3). The test group received 750 mg of NAD+ in normal saline over 6 hours, about 2 mg a minute, and the authors say the dose "was derived empirically and reflects a common dosing regimen in clinics".1

Plasma NAD+ and its metabolites did not change until after the 2 hour sample. The authors state that at 3 µmol a minute NAD+ "is rapidly and completely removed from the plasma for at least the first 2 h". Plasma NAD+ was 398% above baseline at 6 hours (p < 0.0001) and plasma nicotinamide rose by 409%; urinary NAD+ excretion rose by 538% at 6 hours against 30 minutes.1

No adverse events were observed during the infusion in either group. Three liver enzymes were lower at 8 hours in the NAD+ group and bilirubin was higher by 2.75 µmol/L; the authors judged none of the changes clinically significant. They note that no liver marker changed in the saline group, though "low sample number may reduce discrimination sensitivity".1

The study was funded jointly by NAD+ Research Inc. and the Australasian Research Institute. One author is a director of NAD+ Research Inc. and medical director of the Springfield Wellness Center, which uses intravenous NAD+ as a clinical therapy, and another received consulting fees from NAD+ Research Inc.; the infusions were given at that centre.1

5

Human studies

The table lists the human studies of NAD+ itself cited here.

Table 5.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Grant and colleagues, 20191Randomised pilot, saline control11 healthy men aged 30 to 55 (8 NAD+, 3 saline)750 mg intravenous over 6 hoursPlasma NAD+ 398% above baseline at 6 hours (p < 0.0001), no change before 2 hours; no adverse events reported
Reyna and colleagues, 202610Retrospective chart review, NAD+ against nicotinamide riboside (NR), no placebo14 adults: 6 NAD+ and 8 NR500 mg intravenous daily for 4 days; 30 days follow-upAll 6 NAD+ clients reported moderate to severe symptoms during infusion; 4-day average infusion time 97 ± 56.33 against 37 ± 13.08 min for NR
Yu and colleagues, 2026 (heart failure)9Randomised, placebo-controlled, single centre180 adults with ischaemic cardiomyopathy, LVEF 45% or less, NYHA II-III (90 against 90)10 mg intravenous daily for 7 days; 1 monthLVEF at 1 month 45.44 ± 8.55% against 42.44 ± 9.09% (p = 0.024); 6-month MACCE 14.6% against 24.7% (p = 0.089)
Yu and colleagues, 2026 (heart attack)11Randomised, placebo-controlled, single centre120 adults with STEMI after primary PCI (60 against 60)10 mg intravenous daily for 7 days; 30 daysLVEF at 30 days 56.32 ± 8.04% against 53.37 ± 8.12% (p = 0.048); 6-month MACCE 16.7% against 21.7% (log-rank p = 0.482)
Gao and colleagues, 202612Randomised; control group received standard treatment only45 randomised, 38 completed (NAD+ 18, control 20), sudden hearing loss5 mg intramuscular daily during inpatient care, plus standard therapy; 3 monthsHearing improvement 40.21 against 23.06 dB HL (p = 0.010); recovery time (Kaplan-Meier estimate) 62.97 against 175.98 days (p = 0.028)
Kornilov and colleagues, 20263Randomised, placebo-controlled Phase 0/1b trial60 randomised, healthy adults aged 45 to 752000 mg a day of oral LathMized NAD+ (LNAD+) for 5 daysPrimary endpoints, whole-blood intracellular NAD and plasma NAD: intracellular NAD 53% above placebo at day 6; plasma NAD unchanged (p = 0.60)

Gallagher and Emmanuel conclude that for anti-aging or wellness outcomes, clinical effectiveness "remains inconclusive" and that larger randomised trials are needed, "particularly for parenteral approaches". One author of that review reports owning a management services organisation for an aesthetics clinic that does not offer NAD+ infusions or supplementation.4

Deeper analysis: Yu and colleagues, heart failure, 2026

Yu and colleagues (First Affiliated Hospital of the University of Science and Technology of China, American Journal of Cardiovascular Drugs, 2026) randomised 180 adults with heart failure from ischaemic cardiomyopathy, 1:1 by a scheme from an independent statistician. One group received 10 mg of NAD+ in 100 mL of 5% glucose solution (normal saline for people with diabetes) intravenously once a day for 7 days, the other an equivalent placebo, both with guideline-directed therapy. The primary endpoint was the change in LVEF at 1 month, analysed by intention to treat with the last observation carried forward.9

LVEF at 1 month was 45.44% (SD 8.55) with NAD+ and 42.44% (SD 9.09) with placebo (p = 0.024). The secondary results did not reach significance: NT-proBNP at day 7 (p = 0.102), first unplanned heart failure admissions 13.5% against 23.6% (p = 0.078), and no significant differences in structural measures; NYHA class improved in 73.0% against 57.3% at 1 month (p = 0.088) and 53.9% against 39.3% at 6 months (p = 0.115). One person on NAD+ had minor dizziness that settled after about an hour and the drug was stopped as a precaution, and one person on placebo had chest discomfort.9

The authors state that "our study was not sufficiently powered to detect significant differences in clinical events", and that "The 1-month duration of our study may be too short to identify structural changes via transthoracic echocardiography". Funding came from two research funds and "a research grant and study drug supply from Kaifeng Knature Pharmaceutical Co. Ltd.", which the authors say had no part in design or execution; they declare no conflicts of interest.9

Deeper analysis: Reyna and colleagues, 2026

Reyna and colleagues (employees of Restore Hyperwellness, Frontiers in Aging, 2026) reviewed records from a commercial infusion clinic in Austin, Texas. Six clients received 500 mg of NAD+ and eight received 500 mg of NR, each diluted in 500 mL of normal saline, once a day for four days, with each client setting their own infusion rate.10 All six NAD+ clients reported "moderate to severe abdominal cramping, diarrhea, nausea, vomiting, increased heart rates, pain in throat, congestion, and chest pressure during infusion", which "ceased immediately upon infusion completion"; five of eight NR clients reported minor tingling and cramping.10

The groups differed at baseline: mean age 29.4 years with NAD+ and 37.125 with NR, weight 201.14 and 181.56 pounds, systolic blood pressure 131.48 and 120.35. At 30 days alkaline phosphatase (p = 0.04) and HDL cholesterol (p = 0.02) were lower than baseline within the NAD+ group (NAD+ against NR, p < 0.01 and p = 0.03) and HbA1c was lower within the NR group (p = 0.01); ALT, AST, hsCRP, BUN/creatinine and TSH did not change significantly. The authors list "its retrospective design, small cohort size, and dosing constraints", state that "the absence of a placebo-controlled arm limits the generalizability and interpretation of the metabolic biomarker data", and that the study "was designed and executed by a commercial entity that employed the researchers which may have resulted in implicit bias". The paper states that the study "received funding from Restore Hyper Wellness", the authors’ employer, and that NR (Niagen+) "was donated by Niagen Biosciences"; it says neither company was involved in the study design, analysis or writing.10

The other three trials

In the heart attack trial (Yu and colleagues, 2026), LVEF at 30 days was higher with NAD+, and structural measures and 6-month MACCE did not differ significantly. The authors note that "circulating or intracellular NAD⁺ concentrations were not measured". Funding was from university and other research funds, the product used was Coenzyme I for Injection made by Kaifeng Kangnuo Pharmaceutical (the paper does not say who supplied it), and the authors declare no conflict of interest.11

In the hearing loss trial (Gao and colleagues, The Laryngoscope, 2026), the control group received standard treatment only, with no placebo injection, and the NAD+ group started with higher tinnitus and aural fullness scores. Recovery time was a Kaplan-Meier estimate in which people who had not recovered or were lost to follow-up were censored at their last assessment, and the authors cite "a small sample size" among the limits. No adverse events were reported in the NAD+ group; the paper gives no figure for the control group. Knature Biopharmaceutical supported the work in response to an investigator-initiated grant proposal, and the authors declare no conflicts of interest.12

In the oral trial (Kornilov and colleagues, GeroScience, 2026), the product was LathMized NAD+ (LNAD+), which the paper calls "a physicochemically modulated formulation". BioNADRx Holdings, trading as Bryleos, was the sponsor and funder and supplied it. The authors disclose stock options, consultancy fees, shares or investor roles at BioNADRx, and one is its chief executive. The trial was registered on 1 April 2026, after it had been run, and "no secondary clinical, vital-sign, wellbeing, or wearable-derived endpoint survived multiplicity correction".3

Precursors taken by mouth, for comparison

Oral NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are a separate evidence base. Gallagher and Emmanuel report that in people they "consistently demonstrated biochemical target engagement" but that effects on functional, metabolic and vascular outcomes were "heterogeneous and often null or endpoint-specific".4 In the crossover trial of Martens and colleagues, 30 healthy middle-aged and older adults took 1,000 mg a day of NR (NIAGEN; study pills and partial funding came from ChromaDex, Inc.): there were no serious adverse events, 14 treatment-emergent events in 7 of the 30 people, all self-reported as mild, and 2 dropouts for side effects, both in the placebo phase.13

6

Doses reported in studies

None of the studies cited here, and none of the 11 titles from the PubMed query on 16 November 2026, reports a subcutaneous dose of NAD+. The table lists what the cited human studies gave; the app’s 50 to 250 mg a day is its own figure.

Table 6.1Doses reported in studies6 rows
StudyRouteDoseFrequencyLength
Grant and colleagues, 20191Intravenous750 mg in normal salineOne infusion6 hours
Reyna and colleagues, 202610Intravenous500 mg in 500 mL normal salineOnce daily4 days
Yu and colleagues, 2026 (heart failure)9Intravenous10 mg in 100 mL of 5% glucose or salineOnce daily7 days
Yu and colleagues, 2026 (heart attack)11Intravenous10 mg in 100 mL of 0.9% salineOnce daily7 days after PCI
Gao and colleagues, 202612Intramuscular5 mg in 2 mL of salineOnce dailyDuring inpatient treatment
Kornilov and colleagues, 20263Oral2000 mg of LNAD+ (NAD+ 50% of the powder’s mass)Four 500 mg doses a day, plus one extra on days 2 and 35 days

Reports differ with dose and setting. In the 2019 infusion study of 750 mg over 6 hours, no adverse events were observed in 8 men on NAD+ or 3 on saline.1 In the 2026 clinic review of 500 mg daily for 4 days, all 6 NAD+ clients reported the moderate to severe symptoms quoted above during infusion, which ended when the infusion ended; the report separates these "adverse experiences" from "documented adverse events", of which it records none.10

In the 10 mg intravenous trials, one person on NAD+ had minor dizziness in the heart failure trial and one had transient nausea in the heart attack trial, each leading to the drug being stopped, and one person on placebo had chest discomfort in each trial.9,11 In the 5 mg intramuscular hearing trial, no adverse events were reported in the NAD+ group, and in the oral trial symptom incidence was comparable between groups, with one grade 1 nausea event on NAD+.12,3 In the heart attack trial, 3 deaths occurred in the NAD+ group and 2 in the placebo group over 6 months, and none was considered related to the study intervention.11

In 2026 GLP-compliant animal studies by Gu and colleagues, intramuscular NAD+ at 3 mg/kg was the safe dose in beagle dogs, while 10 and 30 mg/kg caused increased heart rate, shortened PR and QT intervals and decreased blood pressure. In rats given 10 to 100 mg/kg intramuscularly daily for 4 weeks, the no-observed-adverse-effect level was 100 mg/kg, with reversible injection-site and sciatic-nerve lesions. The authors declare no competing financial interests.14

The app lists no markers to monitor for NAD+. In the studies, NAD+ itself was hard to track in blood: in the infusion study plasma NAD+ and its metabolites stayed flat for the first 2 hours, in the clinic review the dried blood spot assay could not detect changes, which the authors attribute to insufficient sampling, and in the oral trial the whole-blood intracellular measure rose 53% over placebo while plasma NAD stayed unchanged.1,10,3

The trials in heart disease reported echocardiographic and blood markers: LVEF and NT-proBNP in both, with NT-proBNP at day 7 of 960 against 1,604 (median, p = 0.027) in the heart attack trial and a non-significant difference (p = 0.102) in the heart failure trial.11,9 Liver and kidney function and glucose showed no notable abnormalities in either trial.9,11

FDA’s list of bulk drug substances nominated for compounding under section 503A, updated 14 May 2026, places "Nicotinamide Adenine Dinucleotide (NAD)" in category 1, bulk drug substances under evaluation. A salt form, beta-nicotinamide adenine dinucleotide disodium salt trihydrate, is in category 3, nominated without adequate support.15 None of the FDA documents cited here is a drug label for NAD+.

The Chinese trials used a product described as Coenzyme I for Injection, with national drug approval number H41024721, made by a company named in the papers as Kaifeng Kangnuo or Knature.11,12

The WADA 2026 Prohibited List does not name NAD+ or nicotinamide adenine dinucleotide. Its section M2.2, a prohibited method at all times, covers "Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations".16

None of the studies cited here, and none of the 11 titles from the PubMed query on 16 November 2026, reports NAD+ given under the skin in people, so the app’s subcutaneous route, its 95% bioavailability and its 50 to 250 mg daily range have no human study behind them in the sources cited here.

No cited study measured a plasma half-life for NAD+; one cited paper states about 1.7 hours in its introduction without a reference.3

The studies of NAD+ itself range from 11 to 180 people, and the longest dosing period stated is 7 days. In five of the six the paper names the product’s maker, sponsor, funder or the authors’ employer; the heart attack paper names only the maker.1,10,9,12,3,11 Covarrubias and colleagues note that it remains an open question whether repletion "will have beneficial effects in ageing humans".2

What is the half-life of NAD+?

The app lists a half-life of about 45 minutes for NAD+, and no cited study measured a plasma half-life. A 2026 paper’s introduction states about 1.7 hours for intravenous NAD+, with no reference for the figure.3

What does NAD+ do in the body?

NAD+ is a coenzyme for redox reactions that is central to energy metabolism, and sirtuins, CD38 and PARP enzymes consume it.2

Has NAD+ been studied as an injection under the skin?

A PubMed query on 16 November 2026 for subcutaneous NAD+ in people returned 11 records, and none reports it by title. The human studies used intravenous, intramuscular and oral routes.12,1,3

Is NAD+ approved by the FDA?

None of the FDA documents cited here is a drug label for NAD+. FDA’s 503A list, updated 14 May 2026, places NAD in category 1, bulk drug substances under evaluation.15

Is NAD+ banned by WADA?

The WADA 2026 Prohibited List does not name NAD+. Its section M2.2 prohibits intravenous infusions and injections of more than 100 mL in total per 12-hour period, with an exception for hospital treatments, surgical procedures and clinical diagnostic investigations.16

What are the side effects of NAD+ infusions?

In a 2026 clinic review, all 6 clients given 500 mg of intravenous NAD+ reported moderate to severe symptoms during infusion, including cramping, nausea and chest pressure, which ceased when it ended.10 In the 2019 study of 750 mg over 6 hours no adverse events were observed.1 In the 10 mg intravenous trials one person on NAD+ in each had a minor event and the drug was stopped; in the 5 mg intramuscular trial none was reported in the NAD+ group; in the heart attack trial 3 deaths occurred on NAD+ and 2 on placebo, none judged related.9,11,12

Can NAD+ be absorbed by mouth?

One randomised trial of an oral NAD+ formulation, LathMized NAD+ (60 randomised, 50 in the primary analysis; 5 days), reported intracellular NAD in whole blood 53% above placebo at day 6 with plasma NAD unchanged, and the sponsor was the product’s maker.3 Its introduction states that oral NAD+ bioavailability estimates are below 2%.3

What doses of NAD+ have been used in human studies?

Reported doses were 750 mg over 6 hours and 500 mg a day for 4 days by vein in infusion studies, 10 mg a day by vein and 5 mg a day by muscle in Chinese trials, and 2000 mg a day by mouth for 5 days.1,10,9,12,3

13

References

  1. Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci 2019. PMC6751327
  2. Covarrubias AJ, Perrone R, Grozio A, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol 2021. PMC7963035
  3. Kornilov SA, Hastings WJ, McGrath LF, et al. Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. GeroScience 2026. DOI 10.1007/s11357-026-02399-1
  4. Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev 2026. PMID 41655607
  5. Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One 2012. PMC3407129
  6. Zhu XH, Lu M, Lee BY, et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci U S A 2015. PMID 25730862
  7. Clement J, Wong M, Poljak A, et al. The Plasma NAD+ Metabolome Is Dysregulated in "Normal" Aging. Rejuvenation Res 2019. PMC6482912
  8. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab 2016. PMC4911708
  9. Yu X, Xu J, Cao J, et al. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. Am J Cardiovasc Drugs 2026. PMC12779688
  10. Reyna K, Heinzen G, Patel N, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging 2026. PMC12907335
  11. Yu X, Cao J, Xu Q, et al. Effect of Intravenous Nicotinamide Adenine Dinucleotide on Left Ventricular Function After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Trial. Am J Cardiovasc Drugs 2026. DOI 10.1007/s40256-026-00826-4
  12. Gao M, Guan Y, Yue X, et al. NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial. Laryngoscope 2026. PMC12913733
  13. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018. PMC5876407
  14. Gu J, Xu J, Yang S, et al. Non-clinical safety evaluation of coenzyme I (NAD+): A GLP-compliant systematic study. Biomed Pharmacother 2026. PMID 42748828
  15. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act: categories 1, 2 and 3. Updated 14 May 2026. FDA category list
  16. World Anti-Doping Agency. The 2026 Prohibited List. In effect 1 January 2026. WADA 2026 list